NeuroCare Group

neuroCare provides drug free, side-effect free and sustainable outcomes in therapy for ADHD, depression, chronic pain and for rehabilitation.

neuroConn is our technology brand, a global leader and industry pioneer in non-invasive neuromodulation. neuroCare’s technology brand neuroConn​ has long been a leader in EEG, neurostimulation and neurofeedback technology. Its approach and implementation of slow cortical potentials (SCP) in the treatment of ADHD and epilepsy is considered the world standard in SCP-neurofeedback. Moreover, neuroConn is the leading technology brand in transcranial electric stimulation, co-determining the research in transcranial Direct Current Stimulation (tDCS), transcranial Alternating Current Stimulation (tACS) and transcranial Random Noise Stimulation (tRNS). In addition, its technology is commercially used in pain and rehabilitation management as an Original Equipment Manufacturer (OEM).

For over 10 years neuroCademy (formerly Brainclinics Education) has offered training courses for clinicians and researchers in the use of neuromodulation techniques in clinical practice and research, such as neurofeedback and rTMS. We have trained more than 1,000 professionals from over 30 different countries. Chances are a professional near you has received training from neuroCademy in the past.

Our neuroCare clinics offer specialized and integrated treatment with personalized solutions for ADHD, insomnia, depression and OCD. In these areas neuroCare only employs state-of-the-art and evidence based techniques, integrated and embedded in a clinical-psychological setting. Our integrated and personalised approach shows an efficacy of up to 76% for patients with ADHD and an efficacy of up to 78% for patients with depression - something we are truly proud of. These approaches are backed by over 15 years of scientific research implemented by Brainclinics and now offered by neuroCare. The efficacy of our treatment is published in several peer reviewed scientific publications.